BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37092793)

  • 21. Peptide-targeted dendrimeric prodrugs of 5-aminolevulinic acid: A novel approach towards enhanced accumulation of protoporphyrin IX for photodynamic therapy.
    Tewari KM; Dondi R; Yaghini E; Pourzand C; MacRobert AJ; Eggleston IM
    Bioorg Chem; 2021 Apr; 109():104667. PubMed ID: 33611140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
    Fontana AO; Piffaretti D; Marchi F; Burgio F; Faia-Torres AB; Paganetti P; Pinton S; Pieles U; Reinert M
    J Neurooncol; 2017 Jul; 133(3):497-507. PubMed ID: 28500562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells.
    Karmakar S; Banik NL; Patel SJ; Ray SK
    Neurosci Lett; 2007 Mar; 415(3):242-7. PubMed ID: 17335970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
    Rezaei S; Assaran Darban R; Javid H; Hashemy SI
    Biomed Res Int; 2022; 2022():8540403. PubMed ID: 35281606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme.
    Napier TS; Udayakumar N; Jani AH; Hartman YE; Houson HA; Moore L; Amm HM; van den Berg NS; Sorace AG; Warram JM
    Mol Cancer Ther; 2020 Sep; 19(9):1922-1929. PubMed ID: 32606015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas.
    Kiesel B; Mischkulnig M; Woehrer A; Martinez-Moreno M; Millesi M; Mallouhi A; Czech T; Preusser M; Hainfellner JA; Wolfsberger S; Knosp E; Widhalm G
    J Neurosurg; 2018 Aug; 129(2):341-353. PubMed ID: 29076783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Comparison between human glioblastoma cells and other cancer cell lines.
    Sailer R; Strauss WS; Wagner M; Emmert H; Schneckenburger H
    Photochem Photobiol Sci; 2007 Feb; 6(2):145-51. PubMed ID: 17277837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
    Dikmen M; Gökhaner G; Cantürk Z
    Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma.
    Jeising S; Geerling G; Guthoff R; Hänggi D; Sabel M; Rapp M; Nickel AC
    Photodiagnosis Photodyn Ther; 2022 Dec; 40():103049. PubMed ID: 35932958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methadone enhances the effectiveness of 5-aminolevulinic acid-based photodynamic therapy for squamous cell carcinoma and glioblastoma in vitro.
    Shi L; Buchner A; Pohla H; Pongratz T; Rühm A; Zimmermann W; Gederaas OA; Zhang L; Wang X; Stepp H; Sroka R
    J Biophotonics; 2019 Oct; 12(10):e201800468. PubMed ID: 31140754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells.
    Lawrence JE; Steele CJ; Rovin RA; Belton RJ; Winn RJ
    J Neurooncol; 2016 Mar; 127(1):15-21. PubMed ID: 26643803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
    Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiological oxygen concentration alters glioma cell malignancy and responsiveness to photodynamic therapy in vitro.
    Albert I; Hefti M; Luginbuehl V
    Neurol Res; 2014 Nov; 36(11):1001-10. PubMed ID: 24923209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperthermotherapy enhances antitumor effect of 5-aminolevulinic acid-mediated sonodynamic therapy with activation of caspase-dependent apoptotic pathway in human glioma.
    Ju D; Yamaguchi F; Zhan G; Higuchi T; Asakura T; Morita A; Orimo H; Hu S
    Tumour Biol; 2016 Aug; 37(8):10415-26. PubMed ID: 26846106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
    Robinson P; Coveñas R; Muñoz M
    Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
    Kast RE
    J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme.
    Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A
    Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
    Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
    J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
    Werner M; Lyu C; Stadlbauer B; Schrader I; Buchner A; Stepp H; Sroka R; Pohla H
    Photodiagnosis Photodyn Ther; 2022 Sep; 39():102987. PubMed ID: 35760350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.